Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	29 Oct 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1662.50	2019.00	1871.60 (-11.17%)	21.44	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): All positives built into current valuations BOB Capital Markets Ltd. SUNP reported 11% domestic sales growth led by 5% volume growth from ~14,000 MRs; leads in Rx count across 13 doctor categories pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	ICICI Bank	KRChoksey Target	1420.10	1500.00	1331.85 (6.63%)	5.63	Buy	pdf post cache	Broker Report Consistent performer; No signs of hiccups KRChoksey ICICI Bank delivered a healthy quarter with stable asset quality. Net interest income (NII) grew 9.5% YoY (-11.3% QoQ) to INR 200,480 Mn in Q2FY25. NII was 1.6% higher than our estimates. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Supriya Lifescience	KRChoksey Target	672.30	644.00	603.30 (11.44%)	Target met	Buy	pdf post cache	Broker Report Strong operational performance continue with multiple growth levers KRChoksey Supriya Lifescience revenue slightly missed (-1.2%) our estimate. However, EBITDA and PAT beat our estimates significantly due to lower-than-expected operating expenses, better product mix and better geographical mix. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Sharda Cropchem	Khambatta Securities Reco Target	806.85	729.00	710.25 (13.60%)	Target met	Hold	pdf post cache	Broker Report Price recovery boosts outlook Khambatta Securities Sharda Cropchem Limited (SCL) reported solid growth in 2Q FY25 as revenues increased by 33.8% y-o-y to Rs 776.9 crore. A volume growth of 21% y-o-y was driven by strong performance at the agrochemical segment with Europe being the key contributor. pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Avenue Supermarts	Geojit BNP Paribas Reco Target	4335.80	4471.00	3965.15 (9.35%)	Target met	Buy	pdf post cache	Broker Report AVENUE SUPERMARTS LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Bajaj Finance	Geojit BNP Paribas Reco Target	915.50	7924.00	7022.50 (-86.96%)	Target met	Buy	pdf post cache	Broker Report BAJAJ FINANCE LIMITED Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Nilkamal	IDBI Capital Target	1674.20	2108.00	1946.95 (-14.01%)	Target met	Hold	pdf post cache	Broker Report Nilkamal: Q2FY25 Result Review IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	Cholamandalam	IDBI Capital Target	1583.60	1560.00	1292.40 (22.53%)	Target met	Buy	pdf post cache	Broker Report Cholamandalam Investment and Finance Company: Q2FY25 Result Review IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	ACC	IDBI Capital Reco Target	1817.20	2656.00	2328.65 (-21.96%)	46.16	Buy	pdf post cache	Broker Report ACC: Q2FY25 Result Review IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	29 Oct 2024	The Anup Engineering	Edelweiss Target	2583.60	3500.00	3148.85 (-17.95%)	Target met	Buy	pdf post cache	Broker Report The ANUP Engineering \| Q2FY25 Result Update Edelweiss Robust growth trajectory pdf Copy Link Share on Share on Share on Share on Alert
more loading

Upgrades

Broker research reports for stocks which have been upgraded by brokers. Both recommendation upgrades, as well as share price target upgrades are available .

Sun Pharma (HOLD): All positives built into current valuations

Consistent performer; No signs of hiccups

Strong operational performance continue with multiple growth levers

Price recovery boosts outlook

AVENUE SUPERMARTS LIMITED

BAJAJ FINANCE LIMITED

Nilkamal: Q2FY25 Result Review

Cholamandalam Investment and Finance Company: Q2FY25 Result Review

ACC: Q2FY25 Result Review

The ANUP Engineering | Q2FY25 Result Update

Advisor Screeners